Study protocol for a randomised controlled trial of brief, habit-based, lifestyle advice for cancer survivors: exploring behavioural outcomes for the Advancing Survivorship Cancer Outcomes Trial (ASCOT) by Beeken, RJ et al.
Study protocol for a randomised
controlled trial of brief, habit-based,
lifestyle advice for cancer survivors:
exploring behavioural outcomes for
the Advancing Survivorship Cancer
Outcomes Trial (ASCOT)
Rebecca J Beeken,1 Helen Croker,1 Maggie Heinrich,1 Lee Smith,2 Kate Williams,1
Allan Hackshaw,3 John Hines,4 Michael Machesney,4 Madhavan Krishnaswamy,5
Sharon Cavanagh,6 Rebecca Roylance,7 Alison Hill,7 Kathy Pritchard-Jones,6
Jane Wardle,8† Abigail Fisher1
To cite: Beeken RJ, Croker H,
Heinrich M, et al. Study
protocol for a randomised
controlled trial of brief, habit-





(ASCOT). BMJ Open 2016;6:
e011646. doi:10.1136/
bmjopen-2016-011646
▸ Prepublication history and
additional material is




†In memory of Professor
Jane Wardle.
Received 23 February 2016
Revised 11 August 2016
Accepted 17 October 2016
For numbered affiliations see
end of article.
Correspondence to
Dr Rebecca J Beeken;
r.beeken@ucl.ac.uk
ABSTRACT
Introduction: Positive health behaviours such as
regular physical activity and a healthy diet have
significant effects on cancer outcomes. There is a need
for simple but effective behaviour change interventions
with the potential to be implemented within the cancer
care pathway. Habit-based advice encourages repetition
of a behaviour in a consistent context so that the
behaviour becomes increasingly automatic in response
to a specific contextual cue. This approach therefore
encourages long-term behaviour change and can be
delivered through printed materials. ‘Healthy Habits for
Life’ is a brief intervention based on habit theory, and
incorporating printed materials plus a personally
tailored discussion, that has been designed specifically
for patients with a diagnosis of cancer. The aim of this
trial was to test the effect of ‘Healthy Habits for Life’ on
a composite health behaviour risk index (CHBRI) over
3 months in patients with a diagnosis of breast,
colorectal or prostate cancer.
Method and analysis: A 2-arm, individually
randomised controlled trial in patients with breast,
colorectal and prostate cancer. Patients will be
recruited over 18 months from 7 National Health
Service Trusts in London and Essex. Following
baseline assessments and allocation to intervention or
usual care, patients are followed up at 3 and 6 months.
The primary outcome will be change in CHBRI at
3 months. Maintenance of any changes over 6 months,
and changes in individual health behaviours (including
dietary intake, physical activity, alcohol consumption
and smoking status) will also be explored.
Ethics and dissemination: Ethical approval was
obtained through the National Research Ethics Service
Committee South Central—Oxford B via the Integrated
Research Application System (reference number
14/SC/1369). Results of this study will be
disseminated through peer-reviewed publications and
scientific presentations.
Trial registration number: 17421871.
INTRODUCTION
Smoking, poor diet and low levels of physical
activity are established risk factors for devel-
opment of cancer, but there is now a
growing body of evidence linking them with
survival after diagnosis.1–7 The weight of sci-
entific evidence has led to consensus state-
ments regarding lifestyle change for cancer
survivors.8–10 The most comprehensive of
these recommendations are by the World
Cancer Research Fund (WCRF) who recom-
mend that cancer survivors should follow
guidelines for cancer prevention.10 They
include recommendations for diet, physical
activity, alcohol consumption, tobacco and
body weight.10 They are an important
Strengths and limitations of this study
▪ This intervention is a novel approach to improv-
ing health behaviours of cancer survivors.
▪ This intervention has potential to be delivered
within the cancer care pathway without prohibi-
tive cost.
▪ Owing to the nature of the intervention it will not
be possible to blind participants.
▪ The majority of outcome measures are
self-reported.
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development for the field, although a recent study
demonstrated that oncology health professionals’ aware-
ness of them is suboptimal.11 Previous research has also
shown that the majority of cancer survivors are not
meeting these recommendations,12 but would like
advice post-treatment on how to make positive lifestyle
changes.13 There is therefore a need to translate the
recommendations into effective behaviour change
advice that is appropriate for use with cancer survivors
and can be disseminated cost-effectively through existing
care pathways.
A number of studies carried out in the USA, Canada
and Australia have demonstrated that lifestyle interven-
tions for prostate, breast and colorectal cancer are not
only acceptable to patients, but can successfully improve
more than one health behaviour.14 15 These studies have
demonstrated the effectiveness of tailored, mailed print
materials (eg, two 5-month workbooks and newslet-
ters),14 and of telephone delivered sessions combined
with mailed materials (eg, 11 phone calls over 6 months
combined with a participant handbook, regular motiv-
ational postcard prompts, a pedometer and a quarterly
study newsletter).15 These results are promising, but to
date there is a lack of behaviour change interventions in
a UK healthcare setting. Furthermore, these approaches
are fairly labour intensive. In order to benefit enough
cancer survivors to have a significant public health
impact, an intervention must be cost-effective and feas-
ible to implement in the current clinical pathway. In
other words, it needs to be both brief and inexpensive
so that it can be delivered to all eligible patients by
health professionals within the National Health Service
(NHS), where time and resources tend to be limited.
A potential strategy, which combines elements from
previous successful approaches but within a briefer
format, is to use standard print materials containing
guidelines and simple behavioural skills as the ‘first-line’
intervention, and combine this with a single individually
tailored, brief, telephone discussion. This maximises
coverage, takes advantage of patient preferences for
print materials16 and simple advice17 and also capitalises
on patients’ desire to receive personalised advice, which
is viewed as more relevant than generic communica-
tions.18 19 Furthermore, tailoring can enhance the
effects of health-promoting messages, through stimulat-
ing greater cognitive activity than messages that are not
tailored.20 A recent systematic review also demonstrated
the effectiveness of the telephone for the delivery of life-
style interventions to cancer survivors.21
Previous lifestyle interventions with cancer survivors
have not had a consistent theoretical basis. For example,
the study of mailed tailored materials14 drew on Social
Cognitive Theory22 and the Transtheoretical Model,23
whereas the combination of telephone-delivered sessions
and mailed materials15 was based on Acceptance
Commitment Therapy.24 Studies within other patient
populations suggest that an ideal theoretical basis for
providing behaviour change advice in a brief format is
the habit model.25 According to habit theory, the essen-
tial feature of habits is that they are ‘automatic’ (ie,
require minimal willpower or deliberate effort), and
therefore are well maintained.26 Psychological research
shows that repetition of an action in a consistent context
enables it to become automatic, and once automatic, it
is more resistant to extinction than deliberative (inten-
tional) actions; increasing the likelihood the action will
become a habit and therefore continue over the longer
term.27 There has therefore been increasing interest in
the application of habit theory within the healthcare
context.28
Providing individuals with advice on how to try and
form habits for specific health behaviours (ie, by inte-
grating simple actions into their existing routines, and
associating the new action with a specific context, such
as always taking a walk straight after lunch) is less time
consuming to explain, and easier for patients to imple-
ment than traditional behaviour change strategies.28
There is growing evidence that brief habit-based inter-
ventions can encourage positive changes in dietary and
physical activity behaviours for a range of populations,
including older adults and patients with obesity.29 31 In
particular, one recent study demonstrated the potential
for combining printed materials on habit-based health
behaviour change with a brief discussion with a health
professional.25 However, this approach has not been
tested with cancer survivors.
The proposed study therefore explores the impact of
a behaviour change intervention that has been devel-
oped based on habit theory and which can be delivered
via printed materials and a brief tailored discussion
to all eligible patients with a diagnosis of breast,
colorectal or prostate cancer. This is an individually ran-
domised trial to evaluate behavioural outcomes. If suc-
cessful, it will lead on to a future, large-scale, pragmatic
randomised controlled trial (RCT) with cancer-relevant
outcomes (biomarkers, physical function, adverse




To test the effects of an intervention incorporating tai-
lored advice plus patient materials on a composite
health behaviour risk index (CHBRI) over 3 months in
patients with a diagnosis of breast, colorectal or prostate
cancer, compared with the effects of ‘usual care’.
Secondary research objectives
The main secondary research objectives are to test for
differences in individual health behaviours (physical
activity, sedentary behaviour, diet, smoking and alcohol)
and body mass index (BMI) over the trial period, and
examine whether any changes in CHBRI observed at
3 months are maintained at 6 months. Improvements in
fatigue, sleep and quality of life at 3 and 6 months will
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also be investigated as secondary outcomes. Compliance
and satisfaction with the intervention, alongside basic
costs, will also be recorded.
METHODS AND ANALYSES
The trial will be a two-arm, individually randomised,
parallel-group trial in patients with a diagnosis of breast,
colorectal or prostate cancer, comparing the ‘Healthy
Habits for Life’ intervention with ‘usual care’. Figure 1
illustrates the pathway through the trial.
Participants
Patients who received a diagnosis of breast, colorectal or
prostate cancer in 2012/2013 and who express an inter-
est in taking part in a trial of a lifestyle programme from
seven NHS Trusts across London and Essex.
Recruitment
NHS Trusts were recruited to take part in a cohort study
to explore the health and lifestyle of patients with
cancer postdiagnosis. NHS Trusts were initially recruited
Figure 1 Flow chart of patient recruitment and involvement in study. NHS, National Health Service.
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through London Cancer (five trusts) and two additional
trusts were recruited following the posting of the study
on the Clinical Research Network Portfolio.
Participating sites mail a health and lifestyle question-
naire to all patients diagnosed with breast, colorectal
and prostate cancer in 2012/2013. On the final page of
the questionnaire, patients have the opportunity to
express their interest in taking part in a trial of a lifestyle
programme and to provide their contact details.
Interested patients will be checked for eligibility based
on their responses to the survey. Eligible patients will
be mailed an information sheet and consent form
(figure 1), and receive a reminder telephone call if this
is not returned. The information sheet states that the
study is concerned with promoting a healthy lifestyle
among people who have been diagnosed with breast,
prostate or colorectal cancer, and that we have devel-
oped a lifestyle programme (consisting of a lifestyle
booklet, and telephone call) and are interested in
finding out what patients think about it. No further
details of the intervention will be given. Recruitment is
expected to take place over 18 months to achieve the
required sample size.
Inclusion criteria
The study will be restricted to adults (age ≥18) who are
able to consent for themselves (presumed from comple-
tion of the consent form). Individuals who report a diag-
nosis of non-metastatic (stage I–III) breast, prostate or
colorectal cancer or report that their cancer has not
spread (as a proxy measure for stage), and who state
they are no longer receiving active cancer treatment
(with the exception of oral cancer treatments taken at
home) will be included. If patients report that they do
not know the stage of their disease or whether it has
spread, this will be checked with the NHS Trust from
which they were initially recruited. Similarly, any lack of
clarity around receipt of treatment will be queried with
the appropriate NHS Trust.
Exclusion criteria
Patients will be excluded if they (1) are unable to
provide informed consent due to severe cognitive
impairment, (2) have metastatic disease (stage IV, their
cancer has spread) or (3) are receiving active cancer
treatment requiring hospital admission. Although these
groups may also benefit from lifestyle change, they are
likely to require a different interventional approach with
a higher level of input and supervision. There is not an
upper age limit because previous studies have demon-
strated that interested older patients are able to benefit
and are important to include given the impact of cancer
on functional decline.32
Randomisation
The unit of randomisation will be the patient, and the
allocation ratio will be 1:1. Allocation will be determined
based on minimisation using the software MinimPY (an
open-source customisable minimisation program for
allocation of patients to parallel groups in clinical
trials)33 after the participant has provided informed
consent and baseline data. Randomisation will be strati-
fied by cancer type (breast, colorectal or prostate). The
first participant will be randomly allocated, then each
subsequent participant, will be allocated based on the
imbalance scores (calculated as a function of current
allocations after a hypothetical allocation of the new par-
ticipant in each study arm). The new participant will be
allocated to the arm with the lowest imbalance score.34
A 20% random element will be included in the
algorithm.35
The researcher responsible for randomisation will
inform the trial assistant and trial manager of treatment
allocation using a password-protected spreadsheet. Once
allocated, the trial assistant will inform participants of
their allocation by mailing the intervention materials or
making a brief phone call to those allocated to usual
care stating that all of their data have been received, and
they have not been allocated to receive the booklet.
The intervention
The ‘Healthy Habits for Life’ intervention consists of a
self-guided printed booklet designed to help cancer sur-
vivors make healthy lifestyle behaviours habitual (see
online supplementary material 1). The intervention was
developed through an iterative process with input from
patients, health professionals and experts in the field. A
social marketing company designed the booklet, which
includes a description of recommended health beha-
viours and their potential benefits based on the WCRF
recommendations for cancer survivors.10 Specifically, it
gives advice on nine target areas that participants might
set goals around. These are: (1) being active every day
for 30 min or more (and aiming for 10 000 steps a day),
(2) getting stronger and fitter (doing strength, balance
and stretching exercise twice per week and two 30 min
sessions of vigorous exercise per week), (3) increasing
fruit and veg (five portions or more a day, mostly vegeta-
bles), (4) maximising fibre (choosing wholegrain and
adding fruit, vegetables and pulses to meals), (5) watch-
ing out for high calorie foods and drinks (reducing fat
and sugar and cutting out sugary drinks), (6) reducing
red meat (no more than 500 g across the week), (7)
cutting out processed meat, (8) quitting smoking, and
(9) cutting back on alcohol (no more than 2–3 units per
day for women and 3–4 for men, with at least 2 days
alcohol free). For each target behaviour, there is a list of
new actions that could be incorporated into a daily
routine to help participants meet their goals (ideas for
everyday change).
In addition to the description of the recommended
health behaviours and their benefits, the booklet con-
tains advice on forming healthy habits (eg, repeating
the new actions in a similar context), in line with habit
theory. Based on patient input, it also has quotes from
health professionals endorsing the health behaviours,
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quotes from other cancer survivors encouraging partici-
pation, and links to resources (eg, NHS smoking cessa-
tion services). The booklet also uses evidence-based
behaviour change techniques; goal setting, planning,
self-monitoring and the use of rewards.36 37 ‘Healthy
Life Action Plan’ sheets (see online supplementary
material 2) encourage participants to set goals for the
recommended behaviours, to plan how they will fit the
new action into their existing routines, and to track their
progress throughout the intervention (to support self-
monitoring). Participants are also encouraged to reward
themselves for progress made. During intervention
development, some patients reported a desire for more
information. Because of the need to keep the booklet
brief, there is therefore a corresponding simple website
with additional information on habit theory, the scien-
tific evidence base behind the recommendations, sug-
gestions for home exercise, a frequently asked questions
section and sources of additional information and
support.
Participants in the intervention group will receive a
telephone call from a researcher who will talk partici-
pants through the printed booklet, to check understand-
ing, answer any questions and encourage engagement
with the material. This call will take place ∼1 week after
they have been sent the booklet. During the telephone
call, the researcher will follow a guide (see online
supplementary material 3), which includes talking
through the recommendations, giving advice on
forming healthy habits, discussing with the participant
which health behaviours they are going to change, and
giving instructions for using the ‘Healthy Life Action
Plan’ sheets. Participants will be encouraged to start with
between one and three behaviours, and then add other
changes as and when they feel able to do so.
Participants will be provided with feedback from their
baseline data (including average step count and which
recommendations they appear to be meeting), and
encouraged to focus on behaviours which they could
benefit most from changing.
Researchers delivering the intervention will have a
background in psychology and experience of talking to
patients. They will receive brief (2 hours) training on
delivering the intervention from senior psychologists
and dietitians within the team, including practice going
through the script, how to manage concerns, likely ques-
tions that may come up and problem solving. Quality
control checks will be made, with the trainers observing
each staff member delivering the intervention on at least
one occasion. During these calls the trainers will com-
plete a checklist on adherence to the guide, and provide
feedback at the end of the call.
Usual care
Patients randomised to the control comparator will
receive ‘usual care’. Previous research suggests that
patients do not receive health behaviour advice unless
they specifically ask for it,38 and this has been confirmed
by clinicians involved in the trial. All participants will be
asked at baseline about any other lifestyle programmes
they are involved in, and at follow-up they will be asked
about any changes to their health or treatment.
Measures
Demographics and health status
Demographic data including age, sex, education,
employment status (current and precancer diagnosis),
marital status and living arrangement (who they live
with), and ethnicity will be taken from the initial health
and lifestyle questionnaire (pretrial entry).
Within this questionnaire, patients are also asked what
type of cancer they were diagnosed with in 2012 or 2013
(breast, prostate or colorectal; as the questionnaire is
intended to be sent to these patients) and the date of
their diagnosis. They are asked the stage of their cancer
and if it has spread to any other part of their body. Two
questions ask about cancer treatment including the type
of treatment they had and the time since they com-
pleted their initial treatment for cancer. They are also
asked if they have any other health problems.
The pretrial entry health and lifestyle questionnaire
also includes self-report measures of health behaviours,
anthropometrics and psychosocial variables identical to
those used in the trial (see below). Where participants
are added to the trial within 2 months of their initial
questionnaire, these responses will be used as their base-
line (prerandomisation) for the variables outlined
below. In addition, participants will be sent a pedometer
and invited to complete a dietary recall (further details
below). When patients are added to the trial more than
2 months after their initial questionnaire, they will be
sent a new baseline questionnaire containing the mea-
sures outlined below alongside their pedometer and
dietary recall invite. All measures will be repeated at
3-month and 6-month follow-ups (see table 1). All
follow-up data will be entered by researchers blind to
treatment allocation.
Health behaviours
Measurement of the following health behaviours will
contribute to the calculation of the primary outcome
(CHBRI—see Calculating the primary outcome section
below). Individual health behaviours will be explored as
secondary outcomes.
Physical activity will be assessed using an Omron ped-
ometer, which provides a valid and reliable assessment
of step count.39 Researchers will mail out the pedometer
to participants alongside a pedometer log book that con-
tains instructions on correct wear protocol. The step
count reader on the pedometers will be covered so that
participants will be unable to see their step count (as
this may act as an intervention itself40). Participants will
be asked to record in the log book the time the monitor
is put on in the morning and taken off in the evening
before sleep. Participants will also record in the logbook
any significant non-wear time during the day, for
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example, removed to go swimming or forgot to put on.
Participants will be asked to wear the pedometer on
their waist/in their pocket for 6 consecutive days, and to
then return immediately with the logbook in a provided
freepost envelope. At follow-ups, participants will be
instructed to wear the pedometer the same way that they
wore it at baseline (ie, if they wore it on their waist at
baseline, they should wear it on their waist at follow-up).
Additionally, participants will complete the Godin
Leisure-Time Exercise Questionnaire.41 This measure
has demonstrated favourable validity and reliability
against objective activity monitoring and measures of
fitness42 and has been widely used in the oncology
research context.42 Sedentary behaviour will be assessed
(but will not contribute to the CHRBI) using a single
item on sitting behaviour taken from the International
Physical Activity Questionnaire (IPAQ)43 and two items
on TV viewing taken from the English Longitudinal
Study of Ageing.44 45
Diet will be assessed using repeated multiple pass
dietary recalls completed online by the participant or
by telephone. This is a standard retrospective, dietary
assessment used to capture information on all food
and drinks consumed in the preceding 24 hours. It has
been used in previous dietary intervention trials with
cancer survivors32 46 47 and is recommended for meas-
uring diet in this population.48 Participants will also
complete a self-report questionnaire with items
adapted from the Dietary Instrument for Nutrition
Education (DINE).49 This measure was chosen based
on a review of validated food frequency questionnaires
and a review of dietary assessments used in studies with
cancer survivors. The DINE is a brief measure (mini-
mising participant burden), which was adapted to
ensure that it captured a range of ethnically diverse
foods and where possible, included all foods in the
WCRF guidelines.10
A review of questions in the National Diet and
Nutrition Survey (NDNS) and the Low Income Diet and
Nutrition Survey (LIDNS) was also conducted to ensure
that the main components of the UK diet were
included. The adapted DINE will include 12 questions
to assess dietary fibre (eg, ‘About how many times a
week do you eat a serving of pasta, rice, noodles or cous-
cous?’ with response options: less than once a week or
never/1–2 per week/3–5 per week/6 or more per
week), and 19 questions to assess total fat (eg, ‘About
how many times a week do you eat a serving of cheese
(any except cottage cheese)?’ with response options: less
than once a week or never/1–2 per week/3–5 per
week/6 or more per week). Two further questions will
assess sugar intake. The first measures the consumption
of sugar-sweetened beverages (‘How often do you drink
regular (ie, non-sugar-free) squash, cordials, fizzy drinks
and juice drinks?’ with response options never or rarely/
once a week/2–3 times a week/4–6 times a week/once a
day/twice a day/3 or more times a day).50 The second
question asks about added sugar (About how many
rounded teaspoons of sugar, honey or syrup do you
usually use in a day (eg, in coffee, tea, milk, bread,
cereals, fruit)?). This is an open question where patients
are asked to write the total number of teaspoons per
day. This question was adapted from the National
Health and Nutrition Examination Survey (NHANES)
Dietary Screener Questionnaire.51 Fruit and vegetable
intake will be assessed using a two-item dietary question-
naire.52 53 This measure has been shown to have suffi-
cient validity when compared with objective biological
measures of fruit and vegetable consumption.53
Tobacco usage will be assessed using a question
adapted from those used in the Health Survey for
England.54 Patients will be asked ‘Do you smoke/chew
tobacco at all nowadays?’ (yes/no). This question was
adapted to include tobacco chewing in order to align it
with the WCRF guidelines.10
Alcohol will be assessed using an adapted version of
the Alcohol Use Disorders Identification Test
Consumption Questions (AUDIT-C), a three-item
screening test for active alcohol abuse or dependence
and/or heavy drinking.55 This measure has been found
to perform better than the full length AUDIT question-
naire at identifying heavy drinkers who may benefit from
brief primary care interventions. For this study, the ques-
tions on frequency (‘How often do you have a drink
containing alcohol?’ with response options: never/
monthly or less/2–4 times per month/2–3 times per
week/4+ times per week) and quantity (‘How many
units of alcohol do you drink on a typical day when you
are drinking?’ with response options: 1–2/3–4/5–6/7–
9/10+) will be used to calculate the number of alcoholic
drinks consumed per day. The frequency question was
adapted to include the option ‘every day’ for the
Table 1 Measurement of variables within Advancing Survivorship Cancer Outcomes Trial (ASCOT)
Measurement time point
Type of variable Pretrial entry Baseline Three-month follow-up Six-month follow-up
Demographics x
Health status x
Health behaviours (self-report questionnaires) x x x x
Pedometer and dietary recall x x x
Self-reported anthropometrics x x x x
Psychosocial measures x x x x
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purpose of calculating who was meeting the WCRF
recommendations.10
Anthropometrics
At baseline, participants will be asked to report their
height and weight (preferably weighing and measuring
themselves that day). At 3-month and 6-month follow-
ups, participants will be asked to record their weight
again. This will allow for BMI to be calculated at each
time point as a secondary outcome using the standard
formula of weight (kg)/height (m)2.
Psychosocial measures
Psychosocial measures will be included as secondary out-
comes to assess the broader impact of the intervention
for patients in terms of its effects on their well-being.
Quality of life will be assessed using the five-level
EuroQol-5D questionnaire (EQ-5D-5L).56 Fatigue will be
assessed using the 13-item fatigue subscale of the
Functional Assessment of Chronic Illness Therapy-
Fatigue (FACIT-F) questionnaire.57 Sleep will be assessed
using the Pittsburgh Sleep Quality Index, an 18-item
questionnaire which assesses sleep quality and distur-
bances over a 1-month time interval.58
Intervention acceptability and compliance
Basic costs of the intervention will be recorded (printing
of the booklet, phone and postage charges, staff time)
to provide an indication of the likely expense of imple-
menting this intervention more widely.
Compliance with the intervention, use of the accom-
panying website, and satisfaction with the materials will
be assessed through a set of questions accompanying the
mailed questionnaire at 3-month follow-up. These will
include questions about which aspects of the booklet
they read, reasons for not reading the booklet (if rele-
vant), how useful each section, the phone call and tai-
lored feedback were, if they used the action plans, if
they set goals (and for which behaviours) and if they
achieved their goals, things that prevented them from
achieving their goals, if they made habits, and a measure
of automaticity for each new habit, and use of the
website. Responses will be further explored during quali-
tative interviews (see below). Participants will also be
asked to return copies or photographs of their used
action plans as an indication of how these are being
used. Proportion of intervention calls completed and
the duration of the calls will also be recorded.
Qualitative interviews
At 6 months, a selection of participants (n=20) who
received the intervention will take part in qualitative
interviews. Interviews will explore experiences of the
intervention including barriers and facilitators to com-
pliance, satisfaction and perceived effectiveness of the
different elements of the interventions, and suggestions
for improvement. All interviews will be audio recorded
and transcribed.
Calculating the primary outcome
The primary outcome for this study is a CHBRI, which
will be calculated based on patients’ adherence to the
nine target areas that they are encouraged to set goals
around within the intervention. These behaviours will
be measured as described above. Since a number of key
health behaviours are being targeted within the inter-
vention, rather than assess single behaviours the CHBRI
assesses simultaneous overall change in more than one.
Discussion with oncologists has also indicated that an
overall health behaviour change score would be of more
value than individual behaviours in convincing health
professionals to introduce a lifestyle intervention into
the care pathway.
Furthermore, the use of a composite score allows tailor-
ing of the intervention to patient need and choice. This
scoring system (a composite score based on adherence to
the WCRF guidance vs not) was used previously in the
Iowa Women’s Cohort, and in 2017 cancer survivors was
sensitive enough to show lower all-cause mortality in
those with higher scores59 and to show, in cancer-free
participants, that those who followed 0–1 vs 6–9 of the
guidelines had significantly 35% increased risk of
developing cancer.60 Additionally, using a composite
score, each additional AICR/WCRF guideline met was
associated with 5% reduced risk of developing cancer in
the EPIC cohort.61 A CHBRI has also been successfully
used in a previous lifestyle study in those at risk for
colorectal cancer ‘Project PREVENT’ and was sensitive
enough to detect change in response to a lifestyle inter-
vention involving mailed materials.62
Details for the measurement of each behaviour are
given above. All measurements are made using reliable
and valid tools. Physical activity behaviours (recommen-
dations 1 and 2) will be calculated from pedometer
data, and from the Godin Leisure-Time Exercise
Questionnaire if pedometer data are missing. Dietary
and alcohol behaviours (recommendations 3–8) will be
calculated from dietary recall data, and from self-report
questionnaire measures if recall data are missing.
Tobacco behaviour (recommendation 9) will be calcu-
lated from the self-report questions described above.
Cut-offs for the target behaviours will be based on the
WCRF recommendations (where available) or UK
national guidelines. Participants will be classed as
meeting the recommendations as follows:
1. Daily physical activity: physically active for at least
30 min a day or a daily average of 10 000 steps a
day;
2. Fitness: two 30 min sessions of vigorous, aerobic exer-
cise a week;
3. Fruit and vegetables: five a day or more;
4. Red meat: 500 g per week or less;
5. Processed meat: no processed meat;
6. High calorie foods and drinks: fat 33% or less of total
energy intake, and total sugar ≤50 g per day for
women, 70 g per day for men;
7. Fibre: 18 g per day or more;
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8. Alcohol: two or more alcohol-free days a week, and
average units per day of 2–3 for women, 3–4 for men;
9. Tobacco: non-smoker/non-tobacco consumer.
The nine individual behaviours will be equally
weighted. To calculate CHBRI, at baseline participants
will be assigned an individual score from 0 to 9 depend-
ent on the number of WCRF guidelines met. The same
will be calculated at 3 and 6 months follow-up. In add-
ition to the composite score, change in each behaviour
will be reported as secondary outcomes.
Sample size
This is a large behavioural outcomes trial aimed at deter-
mining whether the ‘Healthy Habits for Life’ brief inter-
vention has an impact on health behaviours, in order to
carry out a future trial including biomarkers and clinical
outcomes. Based on previous lifestyle randomised trials
that have used a CHBRI, the aim is to detect a modest
increase in CHBRI of 0.2 SDs at 3 months, and with
80% power and 5% two-sided statistical significance,
which will require around 700 participants (350 per
group). This will allow for a modest effect size to be
detected in an intention-to-treat analysis, to take into
account people in the intervention group who do not
follow the intervention, as well as those in the control
group who change their habits (both of which would
dilute the effect). Based on a previous study using the
same measure,63 a modest-sized effect (namely, a differ-
ence of 0.2 SDs between the conditions) at 3 months
would represent an increase of 0.24 on the CHBRI
among participants who received the ‘Healthy Habits
for Life’ intervention. In real terms, this would mean
that these participants would be 24% closer to meeting
an additional WCRF recommendation.
The recruitment target is 450 patients into each arm
(there is no aim to recruit specific numbers of patients
by cancer type). This will allow for drop-out, particularly
at the 3-month and 6-month follow-ups. To minimise
loss to follow-up, patients will receive two telephone call
reminders over 6 weeks if they do not return their ped-
ometers or questionnaires and/or do not complete their
dietary recalls.
Data analysis
The primary end point (CHBRI at 3 months) will be
analysed by a researcher blind to treatment allocation.
Unblinding will occur after the primary data analysis is
complete and has been checked and verified by a
second researcher. A full data analysis plan will be devel-
oped and published prior to completion of data collec-
tion. Briefly, baseline characteristics will be reported by
each arm using descriptive statistics. The primary ana-
lysis will be intention to treat. Linear regression analysis
will be used to assess change in CHBRI at 3 months,
with baseline CHBRI scores and treatment group as cov-
ariates. Repeated measures analyses (eg, mixed model-
ling) will be used to analyse the baseline, 3-month and
6-month CHBRI scores together. Missing data will be
explored to see if they are missing at random, and
various sensitivity analyses performed after making dif-
ferent assumptions about the missingness.
Other continuous factors (eg, individual behaviours)
will be analysed using linear regression, and categorical
factors using frequency tables and χ2 tests, and logistic
regression. Exploratory subgroup analyses will be carried
out to examine intervention interactions with gender,
age, education/socioeconomic status, treatment and
tumour type.
With respect to cost-effectiveness, costs associated with
the intervention will be recorded (printing of the
booklet, phone and postage charges, staff time). A full
economic analysis will be conducted within a future,
large-scale, RCT with cancer-relevant outcomes. For the
qualitative data, thematic analysis will be used to identify
the main themes that will form the basis of our results.
LIMITATIONS
This study has several limitations that should be noted.
With the exception of pedometer and dietary recall
data, the outcome measures for the present study will be
self-reported and thus may introduce bias into the data
collection process. For example, participants may under-
report frequency of alcohol consumption on the
AUDIT-C owing to fear of being judged on drinking
habits. Participants may apply similar reporting strategies
when completing other questions relating to health
behaviour. However, all outcome measures have been
developed using reliable and valid tools. For conveni-
ence, the study sample will be recruited from London
and the surrounding areas, which may limit the repre-
sentativeness of the sample to the rest of the UK. A
further limitation is the use of research staff to deliver
the intervention and the detailed assessment on which
the tailored telephone call will be based. If this interven-
tion is to be rolled out within the cancer care pathway,
this assessment will need to be shortened. If the current
trial demonstrates an effect of the intervention on
health behaviours, a pragmatic trial will be needed to
determine the effectiveness of this intervention if deliv-
ered by health professionals within the cancer care
pathway. Future studies will also be required to explore
the importance of the individual components of the
intervention for promoting change. Finally, because of
the nature of the intervention, it will not be possible to
blind participants, but all follow-up data will be collected
and entered by researchers blind to treatment alloca-
tion. Statistical analysis of the primary outcome will also
be performed by a researcher blind to treatment
allocation.
STRENGTHS
The ‘Healthy Habits for Life’ intervention is a novel
approach to improving the health behaviours of people
diagnosed with cancer. Based on habit theory and pro-
viding evidence-based advice on a healthy lifestyle post
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diagnosis in a booklet format, it has the potential to
meet an identified need for an intervention that can be
delivered within the cancer care pathway without pro-
hibitive costs. It is hoped the tailored discussion will
encourage patient engagement and could be replicated
by a health professional within the end of treatment dis-
cussion that patients currently receive as part of their
standard care. This intervention could also be incorpo-
rated within the Living With and Beyond Cancer
Programme introduced in 2014, which includes health
and well-being clinics and cancer care review discussions
with a general practitioner.
The results of this study will assess the impact of
‘Healthy Habits for Life’ on behaviour (an intermediate
outcome) over 3 months and will provide information
on whether any changes are sustained up to 6 months. If
this brief intervention can promote sustained behaviour
change, this will provide the basis for a definitive,
large-scale, national, pragmatic RCT to examine effects
on cancer outcomes of use of the programme in routine
clinical care. Additional funding would be sought for
such a trial from Cancer Research UK. If proven to be
effective in this context, ‘Healthy Habits for Life’ could
make a highly cost-effective contribution to improve-
ments in the long-term survival of people diagnosed
with cancer.
ETHICAL CONSIDERATIONS AND DISSEMINATION
NHS Research and Development approval has been
obtained from all participating NHS Boards prior to the
start of the trial. Potential protocol modifications will be
formally approved by the Research Ethics Committee
before being implemented. The amendments will be
communicated to the trial registries and outlined at the
dissemination of the trial.
Further advice and support on governance and Good
Clinical Practice (GCP) issues will be provided by
Cancer Research UK and University College London
(UCL) Cancer Trials Centre, who provide Standard
Operating Procedures for tasks such as obtaining
consent, managing and archiving data, access to trial
data, training and how to handle breaches of GCP. The
trial was prospectively submitted to the International
Standard Randomised Controlled Trials (13 November
2014) and allocated the number ISRCTN17421871.
UCL is the sponsor of this trial. The Joint Research
Office will monitor and conduct random audits on a
selection of studies in its clinical research portfolio.
Monitoring and auditing will be conducted in accord-
ance with the Department of Health Research
Governance Framework for Health and Social Care,64
and in accordance with the Sponsor’s monitoring and
audit policies and procedures.
This study has been registered for Data Protection at
UCL Records Office (Reference: Z6364106/2014/07/
18). Standard procedures following Data Protection Act
1998, the NHS Code of Confidentiality and GCP will be
implemented throughout the study. All investigators will
have access to the final data set and a completely
de-identified data set will be disseminated to a relevant
data archive for sharing purposes no later than 3 years
after the study close. Study-related documents will be
archived at UCL and each participating site at the end
of the study for 20 years and in line with all relevant
legal and statutory requirements.
An external Trial Steering Committee will meet at
regular intervals to oversee the trial. The committee,
which is chaired by Dr Gill Hubbard, will include two
other independent members, the site principal investi-
gators, the trial co-investigators and a lay representative.
Given the short length of the intervention, the low risk
of harm and the short follow-up of the intervention, an
external Data Monitoring Committee will not be
needed and an interim analysis will not be performed.
All potential adverse effects and unintended effects of
the intervention will be reported to the Trial Steering
Committee and Research Ethics Committee where
appropriate.
Patients who express an interest to participate in the
trial will be posted a consent form to sign and then
return in a freepost envelope (see online supplementary
material 4). On receipt, this form will be co-signed by a
researcher and a copy returned to the participant for
their records. Those who return their signed consent
form will be randomised to the trial provided it is
received before the cut-off date of the end of March
2017. Participants who return their consent forms after
this date will not be included. All participants will be
informed that they are free to withdraw at any time from
the study without giving reasons and without prejudicing
further treatment.
The findings from this study will be disseminated to
academic researchers and to policymakers through
several mechanisms. First, we will employ the usual
avenues for dissemination of academic research includ-
ing conference presentations and journal articles.
Second, we will disseminate the research via social
media outlets such as the UCL—Health Behaviour
Research Centre Twitter account. Third, the UCL and
the Cancer Research UK press offices will coordinate
press releases of key findings. Finally, key findings will
also be fed back to all participating organisations and
patients, and through London Cancer newsletters.
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